Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909512 | 0.97 | CXCR4 (0.91) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2504776 | 0.95 | CXCR4 (0.86) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2509559 | 0.94 | CXCR4 (0.82) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4069793 | 0.94 | CXCR4 (0.87) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| Bromide SCHEMBL5140353 | 0.93 | CXCR4 (0.86) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2506547 | 0.92 | CXCR4 (0.83) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508624 | 0.92 | CXCR4 (0.83) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL3378111 | 0.92 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL12207024 | 0.92 | CXCR4 (0.83) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2508629 | 0.92 | CXCR4 (0.86) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| WO-2008019371-A1 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017025-A2 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| WO-2007022523-A2 | METHODS TO ENHANCE CHEMOTHERAPY | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043012-A1 | Methods to enhance chemotherapy | CXCR4, MCL1, CXCL12 | CXCR4 1/4885CHRM2 1596/4885CYP2D6 4109/4885 |
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 3578/4885CYP2D6 4070/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | CXCR4 9/4885CHRM2 882/4885CYP2D6 1866/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | CXCR4 3/4885CHRM2 3149/4885CYP2D6 4760/4885 |
| US-20100003224-A1 | Combination Therapy | CXCL12, CXCR4, SDF4 | CXCR4 2/4885CHRM2 3833/4885CYP2D6 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.